At the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

Dr. Naonori Kawakubo (Department of Pediatric Surgery, Kyushu University, under the supervision of Professor Tatsuro Tajiri) serving as the principal investigator of the trial titled ‘Phase I Trial of NK Cell-like CD3-negative Cells (GAIA-102) for Recurrent Refractory Neuroblastoma and Pediatric Solid Malignant Tumors, Including Lung Metastasis’ conducted at Kyushu University Hospital, will present a portion of the results from this trial as an interim report at the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology.

The summary of the presentation is as follows:
Title: Phase I Trial of CD3-Negative NK Cell-like Cells (GAIA-102) for Recurrent Neuroblastoma and Other Solid Tumors – Interim Report –
Lead Presenter: Dr. Naonori Kawakubo
Session: General Oral Presentation 7 ‘Radiation Therapy and Novel Treatments’
Presentation Number: OS7-4
Session Date and Time: September 29, 2023 (Friday) 10:10 AM ~ 11:10 AM
Venue: Venue 5 (Highness Hall, 2nd Floor, Royton Sapporo)

https://classic.clinicaltrials.gov/ct2/show/NCT05608148
https://www.congre.co.jp/jspho2023/index.html

Share on